83 related articles for article (PubMed ID: 11394702)
1. Genes of major histocompatibility complex class II influence chronic C hepatitis treatment with interferon in hemodialysis patients.
Dinçer D; Besisik F; Oğuz F; Sever MS; Kaymakoglu S; Cakaloglu Y; Demir K; Türkoglu S; Carin M; Okten A
Int J Artif Organs; 2001 Apr; 24(4):212-4. PubMed ID: 11394702
[TBL] [Abstract][Full Text] [Related]
2. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection.
Alric L; Izopet J; Fort M; Vinel JP; Fontenelle P; Orfila C; Payen JL; Sandres K; Desmorat H; Charlet JP; Duffaut M; Abbal M
Hum Immunol; 1999 Jun; 60(6):516-23. PubMed ID: 10408801
[TBL] [Abstract][Full Text] [Related]
3. Distribution of the human leukocyte antigen class II alleles in Brazilian patients with chronic hepatitis C virus infection.
Corghi DB; Gonçales NS; Marques SB; Gonçales FL
Braz J Med Biol Res; 2008 Oct; 41(10):884-9. PubMed ID: 18925312
[TBL] [Abstract][Full Text] [Related]
4. Association of HLA alleles with response (especially biochemical response) to interferon therapy in Japanese patients with chronic hepatitis C.
Nishiguchi S; Kaneshiro S; Tanaka M; Enomoto M; Akihiro T; Habu D; Takeda T; Fujino K; Tanaka T; Yano Y; Shiomi S
J Interferon Cytokine Res; 2003 Mar; 23(3):135-41. PubMed ID: 12716485
[TBL] [Abstract][Full Text] [Related]
5. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection.
Yenigün A; Durupinar B
J Virol; 2002 Feb; 76(4):1787-9. PubMed ID: 11799174
[TBL] [Abstract][Full Text] [Related]
6. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland.
Wawrzynowicz-Syczewska M; Underhill JA; Clare MA; Boron-Kaczmarska A; McFarlane IG; Donaldson PT
Liver; 2000 Jun; 20(3):234-9. PubMed ID: 10902974
[TBL] [Abstract][Full Text] [Related]
7. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C.
Sim H; Wojcik J; Margulies M; Wade JA; Heathcote J
J Viral Hepat; 1998 Jul; 5(4):249-53. PubMed ID: 9751011
[TBL] [Abstract][Full Text] [Related]
8. [HLA class II alleles and response to hepatitis C treatment with interferon alpha2b].
Piekarska A; Woszczek G; Sidorkiewicz M; Kuydowicz J
Przegl Epidemiol; 2002; 56(1):123-8. PubMed ID: 12150055
[TBL] [Abstract][Full Text] [Related]
9. [Effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin].
Jiao J; Wang JB
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):620-2. PubMed ID: 14572343
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C.
Jiao J; Wang JB
Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):80-3. PubMed ID: 15730926
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in Taiwan.
Tseng KC; Chang CK; Chou AL; Hsieh YH; Tseng CA; Lai NS
Hepatogastroenterology; 2010; 57(99-100):456-61. PubMed ID: 20698208
[TBL] [Abstract][Full Text] [Related]
13. Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II.
Ksiaa L; Ayed-Jendoubi S; Sfar I; Gorgi Y; Najjar HA; Abdallah TB; Ayed K
Viral Immunol; 2007; 20(2):312-9. PubMed ID: 17603847
[TBL] [Abstract][Full Text] [Related]
14. Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran.
Samimi-Rad K; Sadeghi F; Amirzargar A; Eshraghian MR; Alavian SM; Rahimnia R
J Med Virol; 2015 Sep; 87(9):1565-72. PubMed ID: 25970464
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
Alsaran K; Sabry A; Molhem A
Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
[TBL] [Abstract][Full Text] [Related]
16. Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C.
Marangon AV; Moliterno RA; Sell AM; de Moraes CF; Grotto RM; Pardini MC; De Pauli DS; Visentainer JE; Silva GF
Int J Immunogenet; 2012 Aug; 39(4):296-302. PubMed ID: 22284614
[TBL] [Abstract][Full Text] [Related]
17. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
18. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection.
Alric L; Fort M; Izopet J; Vinel JP; Charlet JP; Selves J; Puel J; Pascal JP; Duffaut M; Abbal M
Gastroenterology; 1997 Nov; 113(5):1675-81. PubMed ID: 9352872
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
Kokoglu OF; Uçmak H; Hosoglu S; Cetinkaya A; Kantarceken B; Buyukbese MA; Isik IO
J Gastroenterol Hepatol; 2006 Mar; 21(3):575-80. PubMed ID: 16638102
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles.
De Re V; Caggiari L; Talamini R; Crovatto M; De Vita S; Mazzaro C; Cannizzaro R; Dolcetti R; Boiocchi M
Hum Immunol; 2004 Nov; 65(11):1397-404. PubMed ID: 15556690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
